Abstract:Multiple endocrine neoplasia type 1 (MEN1) is a genetic syndrome in which patients develop neuroendocrine tumors (NETs), including pancreatic neuroendocrine tumors (PanNETs). The prolonged latency of tumor development in MEN1 patients suggests a likelihood that other mutations cooperate with Men1 to induce PanNETs. We propose that Pten loss combined with Men1 loss accelerates tumorigenesis. To test this, we developed two genetically engineered mouse models (GEMMs)—MPR (Men1flox/flox Ptenflox/flox RIP-Cre) and MPM (Men1flox/flox Ptenflox/flox MIP-Cre) using the Cre-LoxP system with insulin-specific biallelic inactivation of Men1 and Pten. Cre in the MPR mouse model was driven by the transgenic rat insulin 2 promoter while in the MPM mouse model was driven by the knock-in mouse insulin 1 promoter. Both mouse models developed well-differentiated (WD) G1/G2 PanNETs at a much shorter latency than Men1 or Pten single deletion alone and exhibited histopathology of human MEN1-like tumor. The MPR model, additionally, developed pituitary neuroendocrine tumors (PitNETs) in the same mouse at a much shorter latency than Men1 or Pten single deletion alone as well. Our data also demonstrate that Pten plays a role in NE tumorigenesis in pancreas and pituitary. Treatment with the mTOR inhibitor rapamycin delayed the growth of PanNETs in both MPR and MPM mice, as well as the growth of PitNETs, resulting in prolonged survival in MPR mice. Our MPR and MPM mouse models are the first to underscore the cooperative roles of Men1 and Pten in cancer, particularly neuroendocrine cancer. The early onset of WD PanNETs mimicking the human counterpart in MPR and MPM mice at 7 weeks provides an effective platform for evaluating therapeutic opportunities for NETs through targeting the MENIN-mediated and PI3K/AKT/mTOR signaling pathways.

Heterozygous<i>Men1</i>Mutant Mice Develop a Range of Endocrine Tumors Mimicking Multiple Endocrine Neoplasia Type 1

Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.

Characterisation of Prostate Cancer Lesions in Heterozygous Men1 Mutant Mice

Pancreatic Beta-Cell-Specific Ablation Of The Multiple Endocrine Neoplasia Type 1 (Men1) Gene Causes Full Penetrance Of Insulinoma Development In Mice

Male Men1 Heterozygous Mice Exhibit Fasting Hyperglycemia in the Early Stage of MEN1.

Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs.

MEN1 mutation analysis in Chinese patients with multiple endocrine neoplasia type 1.

Tumour Suppressor Menin is Essential for Development of the Pancreatic Endocrine Cells

Differentially expressed genes in Men1 knockout and wild‑type embryoid bodies for pancreatic islet development.

Two well-differentiated pancreatic neuroendocrine tumor mouse models

Gene Expression Profiling in Insulinomas of Men1 Beta-Cell Mutant Mice Reveals Early Genetic and Epigenetic Events Involved in Pancreatic Beta-Cell Tumorigenesis.

Menin Epigenetically Represses Hedgehog Signaling in Men1 Tumor Syndrome

Multiple endocrine neoplasia type 1:one case report

Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene

A Novel Germline Mutation of the Men1 Gene Caused Multiple Endocrine Neoplasia Type 1 in A Chinese Young Man and 1 Year Follow-Up

Mutation Analysis in A Chinese Family with Multiple Endocrine Neoplasia Type 1

Intron 9 of MEN1 Gene Mutation-Induced Multiple Endocrine Neoplasia Type 1 : One Case and Analysis of His Pedigree

Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin

Multiple Endocrine Neoplasia Type 1 (MEN I, Wermer Syndrome)

Conditional deletion of Men1 in the pancreatic β-cell leads to glucagon-expressing tumor development.

p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report